Trisomy 8
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (NCT01584531) | Traws Pharma, Inc. | 2012-05-01 |
Track Trisomy 8 automatically
Every clearance here is in the API, with alerts when new ones post.